clinical trial · NCT04158752
Anti-CGRP for Inflammation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia
Trigeminal NeuralgiaGlossopharyngeal NeuralgiaGalcanezumab
brief summary
The investigators will treat patients (targeting enrollment of n=20) who suffer from trigeminal or glossopharyngeal nerve pain in the context of painful small fiber neuropathy. The primary pain-related objective is reduction of pain and reduced use of rescue and other anti-pain medications. Another goal is to monitor and confirm the safety profile established in the migraine population, during previous Phase 3 trials.
started
Jul 24, 2020
primary completion
Jan 4, 2023
completion
Jan 4, 2023
last updated
Feb 2, 2026
official title
Anti-CGRP Neutralizing Antibody for Modulation of Neurogenic Inflammation in Trigeminal and Glossopharyngeal Pain Associated With Small Fiber Neuropathy/Fibromyalgia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol